<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83446">
  <stage>Registered</stage>
  <submitdate>9/12/2008</submitdate>
  <approvaldate>14/08/2009</approvaldate>
  <actrnumber>ACTRN12609000703202</actrnumber>
  <trial_identification>
    <studytitle>A randomised, double blind, placebo-controlled, parallel group, clinical trial to assess the treatment effects of garlic tablet administered for two weeks orally in subjects with pulmonary tuberculosis.</studytitle>
    <scientifictitle>A randomised, double blind, placebo-controlled, parallel group, clinical trial to assess the treatment effects of garlic tablet administered for two weeks orally in subjects with pulmonary tuberculosis</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Pulmonary tuberculosis</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>There are 2 treatment arms:

Randomised allocation to Garcin (1000mg).
 Dosage - 2 tablets per day will be administered orally for the first 2 weeks of the standard antituberculosis regimen.</interventions>
    <comparator>Placebo-lactose pills, but since it lacks the smell of the real drug, the treatment tablets are put in the vicinity of the plastic bags for a week and then the bags would be filled by palcebo. Dosage - 2 tablets per day will be administered orally for the first 2 weeks of the standard antituberculosis regimen.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>sputum smear-negative pulmonary tuberculosis</outcome>
      <timepoint>At Baseline, 4, 8 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Liver Function Tests 'Serum Glutamic Pyruvic Transaminase (SGPT), Serum Glutamic-Oxaloacetic Transaminase (SGOT)' 3X the baseline values plus clinical symptoms, or SGOT, SGPT 5X the baseline values would be considered antituberculosis induced hepatitis.</outcome>
      <timepoint>At Baseline , 2, 4, 8 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients newly diagnosed with smear positive pulmonary tuberculosis admitted to the hospital who receive standard treatment</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Human Immune Deficiency Virus (HIV) positives, confirmed hepatitis at baseline, patients with cirrhosis, renal failure, and known hypersensitivity to garlic, those prone to hemorrhage, and hypotension</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The treatment allocation was randomised by a researcher who is not directly involved in the trial. Central randomization by telephone.</concealment>
    <sequence>Computerized sequence generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/12/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Masih Daneshvari Hospital, National Research Institute of Tuberculosis and Lung Diseases (NRITLD)</primarysponsorname>
    <primarysponsoraddress>Masih Daneshvari Hospital, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Darabad, Tehran</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Masih Daneshvari Hospital, National Research Institute of Tuberculosis and Lung Diseases (NRITLD)</fundingname>
      <fundingaddress>National Research Institute of Tuberculosis and Lung Diseases (NRITLD)
Shaheed Bahonar Ave, Darabad 
TEHRAN 19569,P.O: 19575/154</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Masih Daneshvari Hospital, National Research Institute of Tuberculosis and Lung Diseases (NRITLD)</fundingname>
      <fundingaddress>Masih Daneshvari Hospital, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Darabad, Tehran</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>We could not find any study that has examined the use of Garlic (Allium sativum, garlick) to treat tuberculosis as add on to antituberculosis regimen or to prevent drug induced hepatitis. It has been reported byGholami et al (pharmacy practice, 2006, 4(3): 134) that  Antituberculosis -induced Hepatotoxicity in our region is much higher than western countries (25.9% vs 4.5%) . The proposed study will provide scientifically valid data to date on whether garlic is effective in preventing hepatitis induced by anti tuberculosis regimen or not..</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Masih Daneshvari  Research Ethics Committee</ethicname>
      <ethicaddress>Masih Daneshvari Hospital, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Darabad, Tehran</ethicaddress>
      <ethicapprovaldate>3/11/2008</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Mohammad Reza Masjedi</name>
      <address>Masih Daneshvari Hospital, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Darabad, Tehran.</address>
      <phone>+98 21 20109991</phone>
      <fax />
      <email>mrmasjedi@nritld.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Fanak Fahimi, Payam Tabarsi</name>
      <address>Masih Daneshvari Hospital, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Darabad, Tehran.</address>
      <phone>+98 921940902</phone>
      <fax />
      <email>fahimi@nritld.ac.ir, tabarsi@nritld.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Nader Heidarzadeh, Fanak Fahimi</name>
      <address>Masih Daneshvari Hospital, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Darabad, Tehran.</address>
      <phone>+98 912 2857226</phone>
      <fax>+98 21 22678090</fax>
      <email>fanakfahimi@yahoo.com, fahimi@nritld.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>